Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1833 studies found for:    Bevacizumab
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Condition: Diabetic Retinopathy
Interventions: Procedure: Laser Photocoagulation;   Drug: Bevacizumab
2 Recruiting Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Condition: Glioblastoma Multiforme
Interventions: Drug: TPI 287;   Drug: Bevacizumab
3 Completed
Has Results
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Conditions: Cervical Cancer;   Endometrial Cancer;   Ovarian Cancer;   Vaginal Cancer;   Carcinoma of the Vulva
Intervention: Drug: Avastin
4 Active, not recruiting Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Condition: Melanoma
Interventions: Drug: Bevacizumab Plus Ipilimumab Cohort 1;   Drug: Bevacizumab Plus Ipilimumab Cohort 2;   Drug: Bevacizumab Plus Ipilimumab Cohort 3;   Drug: Bevacizumab Plus Ipilimumab Cohort 4
5 Completed Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: Avastin;   Drug: Tarceva
6 Active, not recruiting Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors
Condition: Solid Tumors
Intervention: Drug: CNTO 95 and avastin
7 Completed
Has Results
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Drug: temozolomide
8 Completed Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
Condition: Macular Degeneration
Interventions: Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
9 Recruiting Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: Bevacizumab;   Drug: BKM120
10 Recruiting Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
11 Unknown  Prospective Randomized Trial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: 24GyE proton and Anti-VEGF;   Drug: 16GyE and anti-VEGF;   Drug: Sham Irradiation and anti-VEGF
12 Recruiting Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Condition: Glioblastoma Multiforme
Interventions: Drug: TPI 287;   Drug: Bevacizumab
13 Completed Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Capecitabine;   Radiation: Radiation Therapy
14 Completed Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
Condition: Glaucoma
Interventions: Drug: Bevacizumab;   Drug: Mitomycin C
15 Unknown  Intralesional Bevacizumab Injection on Primary Pterygium
Conditions: Pterygium;   Inflammation
Interventions: Drug: Intralesional injection of bevacizumab;   Drug: Topical antihistamine and vasoconstrictor
16 Completed Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Placebo
17 Active, not recruiting Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
Conditions: Advanced Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Ovarian Carcinosarcoma
Intervention: Drug: Avastin
18 Terminated
Has Results
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Docetaxel;   Drug: CPT-11;   Drug: Paclitaxel;   Drug: Vinorelbine Tartrate;   Drug: Gemcitabine
19 Completed
Has Results
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis
20 Completed
Has Results
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Conditions: Carcinoma, Renal Cell;   Adenocarcinoma, Renal Cell;   Nephroid Carcinoma,;   Hypernephroid
Interventions: Drug: RAD001(everolimus);   Drug: interferon alfa-2a;   Drug: bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years